Ben Leach

With four full days of programming, dozens of exhibitors, satellite symposia, and thousands of members in attendance, trying to fit everything in at the ONS Annual Congress can prove quite challenging.

The FDA has approved pazopanib for the treatment of patients with advanced soft tissue sarcoma who have previously received chemotherapy.

William G. Wierda, MD, PhD, discussed the management of chronic lymphocytic leukemia at the 16th Annual International Congress on Hematologic Malignancies.

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

This year's ONS Annual Congress marks the first at which Mary Gullatte, PhD, RN, APRN, BC, AOCN, will serve as the organization's president.

A retrospective analysis of the risks of hypothyroidism in patients who received sunitinib and sorafenib is gaining attention in the field of head and neck cancers.

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

A new test specifically designed for breast cancer patients with DCIS appears to be a better indicator of recurrence than other assays for more invasive forms of the disease.

Patients who received cetuximab in combination with a standard adjuvant therapy treatment for colon cancer did not experience improved survival.

For locally advanced breast cancer, molecular profiling may be an effective way to determine which patients respond better to certain therapies.

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

ODAC voted 7-4 (2 abstentions) in support of vincristine sulfate liposomes injection to treat patients with Ph-negative ALL.

ODAC has recommended the approval of pazopanib but ruled against the agent ridaforolimus to treat sarcoma.

The DDIs between Co-Rx medications and targeted OAD is associated with a significant decrease in effectiveness and increased toxicity.

PSA testing was shown to significantly reduce mortality among men, but the test had no effect on all-cause mortality.

Approximately 7% of Americans are infected with oral human papillomavirus (HPV), and men are 3 times as likely to be infected as women.

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Once injectable agents were proven to lower testosterone levels, they became the preferred treatment among patients and their treatment teams.

Vemurafenib nearly doubles the median OS in more than 50% of patients with BRAF V600-mutated metastatic melanoma.

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.

Certain characteristics of patients with CML can affect therapeutic outcomes.

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Two phase III clinical trials showed that nilotinib continues to demonstrate more favorable molecular response levels in patients with Ph CML than imatinib mesylate.

In March, a one-day conference will provide specialists with practical information they need to provide their patients with the best in diagnostic and therapeutic care.

Bevacizumab improved progression-free survival in patients with ovarian cancer but was not shown to affect overall survival.

The 9th International Symposium on Ovarian Cancer and Other Gynecologic Malignancies conference will bring professionals in the field up to date on the latest research into ovarian, uterine, cervical, and endometrial cancers.

Researchers are dissecting new studies regarding targeted therapies as well as combined therapeutic approaches for HPV in the progression of head and neck cancers.

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.